Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women

Climacteric

Volumn 2, Issue 2, 1999, Pages 93-100

  Gaspard, U J ^a   Wery, O J ^a   Scheen, A J ^a   Jaminet, C ^a   Lefebvre, P J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Glucose tolerance; Hormone replacement therapy; Insulin resistance; Menopause

Indexed keywords

C PEPTIDE; DYDROGESTERONE; ESTRADIOL; FATTY ACID; GLUCAGON; GLUCOSE; INSULIN;

ADULT; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032870651     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139909025572     Document Type: Article

References (30)

1. Kreisberg RA. Aging, glucose metabolism and diabetes: current concepts. Geriatrics 1987;42:67-72
2. Walton C, Godsland IF, Proudler AJ, et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993;23:466-73
3. Godsland IF, Walton C, Stevenson JC. Carbohydrate metabolism, cardiovascular disease and hormone replacement therapy. In Berg G, Hammar M, eds. The Modern Management of Menopause. Carnforth, UK: Parthenon Publishing, 1994:231-49
4. Gaspard UJ, Gottal JM, van den Brûle FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995;21:171-8
5. Ford ES, Destefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Am J Epidemiol 1991;133:1220-30
6. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 1995;123:673-5
7. Reaven GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31
8. Scheen AJ. Perspective in the treatment of insulin resistance. Hum Reprod 1997;12(Suppl 1):63-71
9. Lindheim SR, Presser SC, Ditkoff EC, et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the alternating effect of added progestin. Fertil Steril 1993;60:664-7
10. The writing group for the PEPI Trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
11. Voetberg GA, Netelenbos JC, Kenemans P, et al. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994;79:1465-9
12. Burch DJ, Spowart KJ, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β-oestradiol. Br J Obstet Gynaecol 1995;102:243-8
13. Crook D, Godsland IF, Stevenson JC. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. Eur Menopause J 1995;2(Suppl 4):23-30
14. Sodoyez-Goffaux F, Koch M, Dozio N, et al. Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assay of insulin antibodies. Diabetologia 1988;31:694-702
15. Heding H. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975;11:541-8
16. Luyckx AS. Immunoassays for glucagon. In Lefebvre PJ, Unger RH, eds. Glucagon, Molecular Physiology, Clinical and Therapeutic Implications. Oxford: Pergamon Press, 1972:285-98
17. Okabe H, Uji Y, Nagashima K, et al. Enzymatic determination of free fatty acids in serum. Clin Chem 1980;26:1540-3
18. Wolf PM, Madans JH, Finucane FF, et al. Reduction of cardiovascular disease-related mortality among post-menopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94
19. Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol 1994;29:357-75
20. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16
21. Cagnacci A, Soldani R, Carriero PL, et al. Effects of low doses of transdermal 17β-oestradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396-400
22. Cagnacci A, Tuveri F, Cirillo R, et al. The effect of transdermal 17β-oestradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 1997;28:163-7
23. Lobo RA, Pickar JH, Wild RA, et al., for the menopause study group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in post-menopausal women. Obstet Gynecol 1994;84:987-95
24. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Diabetes Care 1998;21:1589-95
25. Crook D, Godsland IF, Hull J, et al. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow-up. Br J Obstet Gynaecol 1997;104:298-304
26. Lindheim SR, Buchanan TA, Duffy DM, et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. J Soc Gynecol Invest 1994;1:150-4
27. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993;76:472-5
28. O'Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in post-menopausal women. J Clin Endocrinol Metab 1995;80:1783-8
29. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-53
30. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 1991;72:642-6